Effect of LY3314814 on the Pharmacokinetics of Warfarin in Healthy Subjects
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Lanabecestat (Primary) ; Warfarin
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca; Eli Lilly and Company
- 24 Mar 2018 Results (n=15) presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 17 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.